drugset / Trial / NCT05006911

Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms

NCT05006911

Phase 1 Unknown 11 enrolled Optall Vision
NaSingle-groupOpen-labelTreatment

Summary

Safety and Efficacy of Pilocarpine, Brimonidine, Oxymetazoline, Hyaluronic acid, Bromfenac (PBOHB) ophthalmic compound to improve uncorrected near vision in healthy presbyopic patients one hour after instillation.

Timeline

Start
2021-08-14
Primary completion
2021-09-01
Completion
2021-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Brimonidine Small molecule
Subject Bromfenac Other / unclassified
Subject Hyaluronic Acid Other / unclassified
Subject Oxymetazoline Other / unclassified
Subject Pilocarpine Unknown

Indications